📄 What This Document Is

This is a 6-K filing from Alpha Tau Medical, which is a report for the U.S. Securities and Exchange Commission (SEC) that foreign companies use to share important news. In this case, it's two major press releases about their pancreatic cancer treatment trials. It's not a routine financial report, but rather a clinical and strategic update for investors.

🏢 What The Company Does

In simple terms, Alpha Tau Medical is a cancer therapy company. They developed a treatment called Alpha DaRT® (Diffusing Alpha-emitters Radiation Therapy). Instead of using external radiation beams, their technology involves implanting tiny "seeds" directly into a tumor. These seeds release short-lived, powerful alpha particles that aim to destroy the cancer cells very precisely while sparing the healthy tissue around them.

🩺 The Huge Unmet Medical Need

Pancreatic cancer is one of the deadliest cancers, and the company is targeting a very specific, tough-to-treat situation.

• The Problem: In Europe alone, about 140,000 people are diagnosed with pancreatic cancer yearly. Around 30% of them (~42,000 patients) have "locally advanced" disease. This means the tumor has grown into critical blood vessels so it can't be surgically removed, but it hasn't yet spread to other organs.
• The Gap in Care: These patients often get intensive chemotherapy (mFOLFIRINOX), but once that's done, there is no standard next step. Their prognosis is poor, and they have very few options left. That's the gap Alpha Tau is trying to fill.

🇪🇺 ACAPELLA Trial: A European Milestone

Alpha Tau announced they successfully treated the first patient in Europe in their ACAPELLA clinical trial.

• What Happened: The procedure was performed at CHU Grenoble Alpes in France by Professor Gaël Roth's team. This marks the first use of Alpha DaRT for pancreatic cancer in Europe.
• Trial Details: ACAPELLA will enroll up to 40 patients in France. It's testing Alpha DaRT combined with the chemotherapy drug capecitabine for patients with inoperable locally advanced pancreatic cancer who have just finished their first-line mFOLFIRINOX chemo.
• Why It Matters: This first treatment kicks off a key European trial. The company highlighted that this timing is strategic, coming just before a major medical conference (Digestive Disease Week 2026 in Chicago), where they can share this progress with top doctors.

🇺🇸 IMPACT Trial: FDA Gives a Green Light for Expansion

On the same day, Alpha Tau shared that the U.S. FDA approved an expansion of their other pancreatic cancer trial, the IMPACT study.

• The Expansion: The FDA said "yes" to adding a new group of 10 patients to the trial. These patients will receive Alpha DaRT combined with a different standard chemo, gemcitabine/nab-paclitaxel (brand name Abraxane®).
• Growing the Study: With this approval, the total size of the U.S., Canada, and Israel-based IMPACT trial increases from 30 to 40 patients.
• Why It Matters: This is huge for strategy. It means Alpha DaRT is now being tested alongside both of the main first-line chemotherapy backbones for pancreatic cancer. This gives the company a much broader data set and a clearer path for future development.

🧭 What This Signals: A Global Strategy in Motion

These two announcements, coming together, show a clear and focused plan.

• Parallel Tracks: Alpha Tau is now running two major, multicenter trials simultaneously – ACAPELLA in Europe and IMPACT in North America/Israel. This is a significant operational milestone for a company their size.
• Targeting the Core Problem: Both trials are aimed at a population with a massive unmet need (locally advanced and metastatic pancreatic cancer patients). Success here could be transformative.
• Building the Evidence: As Chief Medical Officer Robert Den, MD, noted, this expansion helps them understand how their therapy might work with different treatments and in different patient groups, which is crucial for designing future studies.

🔮 What's Next

The immediate next steps involve growing these trials and sharing data.

• Trial Recruitment: The company now expects to finish patient recruitment for the IMPACT trial in Q3 2026 (it was originally planned for Q2). The ACAPELLA trial in France is now actively enrolling.
• Data & Conferences: They will be presenting their pancreatic cancer program at major medical conferences throughout 2026. Investors will be watching closely for safety and early efficacy data from both trials.
• Strategic Goal: The ultimate goal is to prove Alpha DaRT can be a safe and effective new option for patients who currently have no good path forward after chemotherapy.

💡 Why This Matters

This filing isn't about quarterly sales or profits—it's about de-risking the company's future pipeline. For a clinical-stage biotech like Alpha Tau, success is measured in trial progress and regulatory milestones. By simultaneously advancing trials in two major regions (US & EU) and expanding them to cover the main treatment standards, they are significantly increasing their chances of gathering the positive data needed to eventually seek approval and commercialize Alpha DaRT for pancreatic cancer. This moves the needle from "experimental idea" to "credible treatment candidate."

🧠 The Analogy

Think of Alpha Tau as a company with a powerful new tool for fixing a specific type of broken pipe (a tumor). They’ve just started two repair crews in different neighborhoods (the US and Europe). The ACAPELLA announcement is the European crew finishing its first successful repair job. The IMPACT announcement is like getting a permit to use their tool with a second, common type of plumbing material (gemcitabine), doubling their potential repair jobs and proving the tool's versatility.

🧩 Final Takeaway

Alpha Tau is executing a focused, global strategy to attack one of oncology's toughest challenges. By launching its first European pancreatic cancer trial and expanding its U.S. trial on the same day, the company is aggressively building the clinical evidence needed to potentially turn Alpha DaRT into a new standard of care for patients with inoperable pancreatic cancer.